https://www.selleckchem.com/products/GDC-0449.html
This study explored the impact of multiple prognostic factors on patient overall survival (OS) and real-world progression-free survival (rwPFS) for patients with hormone receptor-positive (HR )/human epidermal growth factor 2 negative (HER2 ) metastatic breast cancer (MBC). This retrospective study used electronic health record data of patients in the United States from community oncology practices from January 1, 2008 to April 30, 2017. Eligibility included HR /HER2 MBC diagnosis in 2008 or later and prior systemic therapy for MBC. An
Like
Comment
Share
